RNAi News and Research

RSS

Scientists devise powerful algorithm to improve effectiveness of research technology harnessing RNAi

Scientists at Cold Spring Harbor Laboratory have devised a powerful algorithm that improves the effectiveness of an important research technology harnessing RNA interference, or RNAi.

7 Dec 2014

UNC researchers develop new approach to block KRAS oncogene

Researchers from the UNC School of Medicine and colleagues at The University of Texas MD Anderson Cancer Center have developed a new approach to block the KRAS oncogene, one of the most frequently mutated genes in human cancer.

14 Nov 2014

Researchers develop 'smart bomb' to attack B-lineage ALL

Fatih Uckun, Jianjun Cheng and their colleagues have taken the first steps towards developing a so-called "smart bomb" to attack the most common and deadly form of childhood cancer — called B-lineage acute lymphoblastic leukemia (ALL).

6 Nov 2014

Promising new approach for combating colorectal cancer

Scientists at the University of York are working on a promising new approach for tackling colorectal cancer, the second most common cause of cancer-related death.

23 Sep 2014

Internal production of hydrogen peroxide can lead cells to exit cell cycle and become senescent

What happens inside cells when they detect the activation of a cancer-inducing gene? Sometimes, cells are able to signal internally to stop the cell cycle. Such cells are able to enter, at least for a time, a protective non-growth state.

30 Aug 2014

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs.

26 Aug 2014

Antifungal drug resistance evoked through RNAi-dependent epimutations

Microorganisms like bacteria and fungi can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs.

27 Jul 2014

Doctor maps path of discovery for developing potential anticancer agent

The journal Cancer Cell today published research led by Dr. Tak Mak mapping the path of discovery to developing a potential anticancer agent.

18 Jul 2014

Researchers identify new suppressor of cancer metastasis

Among patients with deadly cancers, more than 90 percent die because of metastatic spread of their disease. Looking to target a key pathway in order to interfere with the processes that lead to tumor spread, a research team led by Irwin H. Gelman, Ph.D., of Roswell Park Cancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tumors.

14 Jul 2014

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

16 Jun 2014

Scientists find out what goes wrong in cancer cell

Cancer - about one in three Europeans is confronted with this diagnosis during their lifetime. Scientists at the German Cancer Research Center DKFZ in Heidelberg are investigating the development of cancerous cells to find out how their growth is controlled and what goes wrong in a cancer cell.

11 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Study: RNAi silencing strategy blocks production of mutant huntingtin protein

A targeted gene silencing strategy blocks production of the dysfunctional huntingtin (Htt) protein, the cause of Huntington's disease, a fatal, inherited neurodegenerative disorder.

22 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

29 Mar 2014

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Spark Therapeutics and Genable Technologies announced today that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038.

25 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

UMass Medical School (UMMS) recognizes the launch today of Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience, to develop life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS).

13 Feb 2014

RNA interference approach holds great promise for treating cancer and other diseases

Inspired by tiny particles that carry cholesterol through the body, MIT chemical engineers have designed nanoparticles that can deliver snippets of genetic material that turn off disease-causing genes.

12 Feb 2014

RNAi-based screening offers MPM treatment hope

Research using RNA interference-based screening has identified several potential targets for the treatment of malignant pleural mesothelioma.

31 Jan 2014